Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position.
about
Molecular determinants of blood-brain barrier permeationBarrier mechanisms in the Drosophila blood-brain barrierTargeting transporters: promoting blood-brain barrier repair in response to oxidative stress injuryP-Glycoprotein Transport of Neurotoxic PesticidesP-glycoprotein modulates morphine uptake into the CNS: a role for the non-steroidal anti-inflammatory drug diclofenacChallenges of using in vitro data for modeling P-glycoprotein efflux in the blood-brain barrier.Role of (drug) transporters in imaging in health and disease.Pharmacologic Profile of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist, for the Treatment of Opioid-Induced Constipation.Predicting the outer boundaries of P-glycoprotein (P-gp)-based drug interactions at the human blood-brain barrier based on rat studies.Mechanistic modeling of monocarboxylate transporter-mediated toxicokinetic/toxicodynamic interactions between γ-hydroxybutyrate and L-lactate.Regulation of ABC transporters at the blood-brain barrier.NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancerFactors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging Study.In Vivo Imaging of Human MDR1 Transcription in the Brain and Spine of MDR1-Luciferase Reporter Mice.ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B-Driven Brainstem Glioma Model.Pilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood-Brain BarrierPhysiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approachBioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development.Reversible dimers of the atypical antipsychotic quetiapine inhibit p-glycoprotein-mediated efflux in vitro with increased binding affinity and in situ at the blood-brain barrier.Overcoming the blood-brain barrier in chemotherapy treatment of pediatric brain tumors.Using positron emission tomography to study transporter-mediated drug-drug interactions in tissues.In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery.Drug transporters in the central nervous system.Improving drug delivery to primary and metastatic brain tumors: strategies to overcome the blood-brain barrier.Mechanisms and therapeutic potential of inhibiting drug efflux transporters.Clinical Applications of Simultaneous PET/MR Imaging Using (R)-[11C]-Verapamil with Cyclosporin A: Preliminary Results on a Surrogate Marker of Drug-Resistant Epilepsy.Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain.Actin filament-associated protein 1 (AFAP-1) is a key mediator in inflammatory signaling-induced rapid attenuation of intrinsic P-gp function in human brain capillary endothelial cells.ABC transporters at the blood-brain barrier.Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters.Effect of P-glycoprotein inhibition at the blood-brain barrier on brain distribution of (R)-[11 C]verapamil in elderly vs. young subjects.Use of PET Imaging to Evaluate Transporter-Mediated Drug-Drug Interactions.Imaging transporters: Transforming diagnostic and therapeutic development.Review of Transporter-Related Postmarketing Requirement or Postmarketing Commitment Studies.Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites.Probenecid, an organic anion transporter 1 and 3 inhibitor, increases plasma and brain exposure of N-acetylcysteine.Examining the Uptake of Central Nervous System Drugs and Candidates across the Blood-Brain Barrier.Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation.
P2860
Q26797482-4570A81C-4DBE-4B5E-8EEE-664462F376D3Q28083620-F1A13918-BB75-4761-B3A7-868D63D9BE1FQ28088708-6D79466A-3BA3-4F24-83B0-EC48D8C18B61Q28389145-C1D7472C-E36E-4E8C-A265-D01FD7CB56C8Q28539683-FE1649AD-07D6-4E27-84C0-A1B31D393150Q30651426-A0A8EA93-9C54-4091-B59D-A6E54FF2D129Q30854787-2D6BD2B3-31C0-4A5A-A06A-1E4263F7CC9EQ33588365-763BFD36-F36B-4E53-809A-074125BBC112Q33651025-7438E593-9C25-411F-A8CC-D2EC3FBB1DAFQ33804002-8767C068-53F5-4ACD-B8A1-951DEEF65A84Q35186642-56994858-714C-4413-9374-A6B55A1F31AFQ35805489-723C7B0E-7DE9-4A50-BABB-4A08DC787D22Q36049576-EE57CF56-89D9-4F69-A93D-AEB9B7B78FA8Q36186141-9DCB0E3C-5787-4140-9A41-498A45D9931DQ36186153-87963065-11A2-404C-9CA2-073D1AF02314Q36918220-998449E5-7593-4403-A5AB-2B51A30C0DC7Q37164563-CDAE205B-A4DA-4A5B-8A9B-242A4D2F877DQ37207750-0C07F465-62CB-4EC8-B53D-20F575617311Q37409373-F267A02D-322A-4DB6-B692-D400D15A2982Q37701128-C7BDBC74-BDCA-45D3-9002-25EE04934CACQ37709400-F08988B5-941E-44EB-B300-17AEB8BC49BDQ38133407-EDD63E98-914D-4AF4-BF4F-AD23C15817FFQ38200490-CAD8D08B-7A1C-4AD7-AAB6-0A479FBD73B2Q38214334-6C00EA48-3B96-4315-81AB-8BB4818406EBQ38342677-F069F6A0-9D43-4A36-9525-5E5AD01C9434Q38351134-22007766-7F69-467A-9EE3-E45970196009Q38388828-D8C38E5F-CC95-4C5F-9447-BA0B584B20F7Q38420352-508C8682-70BF-4852-908D-9A93CD51E192Q38570611-8D2259A8-1541-4B69-B651-3D3BB8BC5408Q38719997-2BD64286-1CBC-433F-AB0C-112F92CAB9FFQ38783122-614A4441-334E-4F6F-BA22-69F20E374A74Q38811728-07C25C78-B7F7-4C96-99DC-444CF0235027Q38841102-B0DA9C38-D59E-4C60-AF91-157ADCE942D7Q38844653-F4CB35D2-813F-49D5-8003-E00C89058BEDQ38871905-0B296456-0C13-410C-B3B5-ECB807092A61Q38888355-161E5D9E-53A4-4C62-AD80-6A1EFF072580Q38888365-82C99231-1956-4AD3-A756-C62F475E1F8CQ39698411-711CFE82-CC14-4709-9740-68D4DA838A39Q39754769-D1C3628C-512C-46DC-9D92-FE1CDB2A5A22Q40036535-8BB8A258-A543-4D80-A531-98A0D772F671
P2860
Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Why clinical modulation of eff ...... e ITC evidence-based position.
@en
type
label
Why clinical modulation of eff ...... e ITC evidence-based position.
@en
prefLabel
Why clinical modulation of eff ...... e ITC evidence-based position.
@en
P2093
P2860
P356
P1476
Why clinical modulation of eff ...... he ITC evidence-based position
@en
P2093
D L Bourdet
International Transporter Consortium
J C Kalvass
M J Zamek-Gliszczynski
P2860
P356
10.1038/CLPT.2013.34
P407
P577
2013-02-14T00:00:00Z